PMID- 8789384
OWN - NLM
STAT- MEDLINE
DCOM- 19970409
LR  - 20190512
IS  - 0007-1188 (Print)
IS  - 0007-1188 (Linking)
VI  - 117
IP  - 2
DP  - 1996 Jan
TI  - Release of vasopressin and oxytocin by excitatory amino acid agonists and the 
      effect of antagonists on release by muscarine and hypertonic saline, in the rat 
      in vivo.
PG  - 309-14
AB  - 1. It has been claimed that glutamate is the dominant excitatory neurotransmitter 
      in neuroendocrine regulation. The evidence is derived mainly from in vitro 
      experiments. 2. We have investigated in vivo a possible role of excitatory amino 
      acids (EAAs) in the neural control of release of vasopressin (AVP) and oxytocin 
      from the neurohypophysis. 3. In rats under ethanol anaesthesia in which a 
      diuresis was maintained by a constant fluid load, the i.c.v. injection of 
      glutamate and the synthetic agonists alpha-amino, 
      3-hydroxy-5-methyl-isoxazole-4-propionate (AMPA) and N-methyl-D-aspartate (NMDA) 
      produced an antidiuretic response (ADR) which was abolished by an AVP antagonist. 
      For AMPA and NMDA it was shown that this ADR was accompanied by increased urinary 
      excretion of AVP and oxytocin. 4. The selectivity of antagonists was tested in 
      this system. D-2-Amino-5-phosphonopentanoate (D-AP5) blocked the responses to 
      NMDA but not to AMPA; 6-cyano-7-nitroquinoxaline-2, 3-dione (CNQX) blocked the 
      responses to both agonists. 5. The ADR to muscarine and hypertonic saline i.c.v., 
      and the increase in excretion of AVP and oxytocin in response to muscarine, were 
      blocked by CNQX but not by D-AP5. 6. The results suggest that hypertonic saline 
      releases AVP and muscarine releases both AVP and oxytocin, at least in part, by 
      activating a glutaminergic input to the SON and PVN involving an AMPA receptor. 
      This input could function as a terminal interneurone in afferent neural pathways 
      to these nuclei.
FAU - Bisset, G W
AU  - Bisset GW
AD  - Division of Neurophysiology, National Institute for Medical Research, London.
FAU - Fairhall, K M
AU  - Fairhall KM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 0 (Excitatory Amino Acid Agonists)
RN  - 0 (Excitatory Amino Acid Antagonists)
RN  - 0 (Muscarinic Agonists)
RN  - 0 (Saline Solution, Hypertonic)
RN  - 0 (Vasoconstrictor Agents)
RN  - 11000-17-2 (Vasopressins)
RN  - 50-56-6 (Oxytocin)
RN  - 6384-92-5 (N-Methylaspartate)
RN  - 6OTE87SCCW (6-Cyano-7-nitroquinoxaline-2,3-dione)
RN  - 77521-29-0 (alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid)
RN  - 7T101UWZ5W (Muscarine)
SB  - IM
MH  - 6-Cyano-7-nitroquinoxaline-2,3-dione/administration & dosage/pharmacology
MH  - Animals
MH  - Diuresis/drug effects
MH  - Excitatory Amino Acid Agonists/administration & dosage/*pharmacology
MH  - Excitatory Amino Acid Antagonists/administration & dosage/*pharmacology
MH  - Injections, Intraventricular
MH  - Male
MH  - Muscarine/*pharmacology
MH  - Muscarinic Agonists/*pharmacology
MH  - N-Methylaspartate/administration & dosage/pharmacology
MH  - Oxytocin/*metabolism
MH  - Rats
MH  - Rats, Wistar
MH  - Saline Solution, Hypertonic
MH  - Urodynamics/drug effects
MH  - Vasoconstrictor Agents/*metabolism/pharmacology
MH  - Vasopressins/*metabolism/pharmacology
MH  - alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid/administration & 
      dosage/pharmacology
PMC - PMC1909267
EDAT- 1996/01/01 00:00
MHDA- 1996/01/01 00:01
PMCR- 1997/01/01
CRDT- 1996/01/01 00:00
PHST- 1996/01/01 00:00 [pubmed]
PHST- 1996/01/01 00:01 [medline]
PHST- 1996/01/01 00:00 [entrez]
PHST- 1997/01/01 00:00 [pmc-release]
AID - 10.1111/j.1476-5381.1996.tb15192.x [doi]
PST - ppublish
SO  - Br J Pharmacol. 1996 Jan;117(2):309-14. doi: 10.1111/j.1476-5381.1996.tb15192.x.